Patheon IncTSX: PTI

Patheon Announces Executive Management Appointments

· Issued by Patheon Inc via CNW

TORONTO, May 14 /CNW/ - Patheon Inc. (TSX: PTI), one of the world's leading pharmaceutical service providers, today announced the following executive management appointments:

-   Eric W. Evans as Chief Financial Officer of Patheon Inc.,

-   Paul M. Garofolo as Senior Vice President and Chief Information
    Officer,

-   Warren A. Horton as Vice President Global Quality Operations, and

-   Doaa A. Fathallah as Senior Vice President, General Counsel Europe
    and Global Pharmaceutical Development Services.

Wes Wheeler, Patheon's Chief Executive Officer and President, provided a brief explanation of the changes:

"Eric Evans will be responsible for managing the company's financial function, and will work with me and our executive team as we create strategic and operational improvements in the business."

Eric brings over 24 years experience in various financial leadership roles in the pharmaceutical industry following a significant career in the steel industry. He joins Patheon most recently from Novartis AG. a provider of healthcare solutions including medicines, generic pharmaceuticals, preventative vaccines and diagnostic tools, and consumer health products. He has experience in all aspects of finance as well as extensive operating, analytical, leadership, and business development experience.

John H. Bell, Chief Financial Officer, will leave Patheon at the end of the month to pursue new opportunities. "The company owes John Bell a great deal for his stewardship of our finance organization through a difficult period at Patheon. We wish him the best" said Wheeler.

"Paul Garofolo is a proven leader with a track record of developing and stewarding long-term global Information Technology strategies and implementing new applications and processes. I am confident he will lead Patheon to cost effective global IT platforms. Paul will have responsibility for Information Technology globally including the development and implementation of a five year global IT Master Plan for Patheon. In addition he will assume responsibility for 'The Patheon Advantage', Patheon's lean six sigma excellence program" said Wheeler.

Paul has an extensive 14 year background in information technology and management consulting most recently with Valeant Pharmaceuticals where he was the Chief Information Officer. He has led all aspects of global IT organizations including development and implementation of long-term IT strategies as well as implementation of new applications and processes.

"Doaa Fathallah will be responsible for all legal matters for Europe and Global Pharmaceutical Development Services" Wheeler continued.

Doaa joins Patheon from Valeant Pharmaceuticals International where she was General Counsel Europe, Middle East & Africa (EMEA) and was responsible for all legal matters in the EMEA region. In addition to her corporate experience Doaa has extensive experience in all aspects of corporate and business law from her time in private practise where she represented privately held and publically traded companies.

"Warren Horton will be responsible for establishing a new Quality System to be consistently applied at all Patheon sites. He will also ensure that the company meets all regulatory requirements for quality and compliance."

Warren brings over 10 years experience in the pharmaceutical industry to Patheon most recently from DSM Pharmaceuticals Inc. where he was responsible for quality assurance and regulatory affairs. In addition he has experience dealing with a large variety of dosage forms, efficient production and quality control and assurance in a variety of liquid and semi solid topical products.

"I am delighted to welcome these executives to the Patheon leadership team. One of my near-term priorities has been to strengthen and rebuild the executive team for Patheon. These individuals bring proven track records, expertise and strong leadership" Wheeler concluded.

ABOUT PATHEON

Patheon (TSX:PTI; www.patheon.com) is a leading global provider of drug development and manufacturing services to the international pharmaceutical industry. Patheon operates a network of 10 manufacturing and six development facilities in the United States, Canada and Europe, employing more than 4,700 people and serving a customer base of 270 pharmaceutical and biotechnology companies.

Caution Concerning Forward-Looking Statements

This news release may contain forward-looking statements which reflect management's expectations regarding the Company's future growth of operations, performance (both operational and financial) and business prospects and opportunities. These statements are made in the context of the risks and uncertainties that are outlined in the Company's public documents, which can be accessed on our website at www.patheon.com or on SEDAR at www.sedar.com.

%SEDAR: 00001700E

Patheon Inc on 6ix

Story so far

Earlier from Patheon

Later from Patheon

All Patheon news releases